AllSight
Companies · HROW · Pharmaceutical Preparations

HARROW, INC. (HROW)

HARROW, INC. (HROW) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

HARROW, INC. (HROW) stock — financials & valuation

Key numbers for HARROW, INC. (HROW): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 35/100 — a percentile rank of HARROW, INC.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$1.2B
P / S4.2×
EV / EBITDA74.4×
Gross margin73.3%
Operating margin-1.0%
Net margin-13.5%
Return on equity-244.9%
ROIC-1.4%
Revenue growth21.1%
Debt / equity19.2×
Dividend yield0.0%

Is HARROW, INC. overvalued? P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from HARROW, INC.’s own financial statements and shown as context, never as advice.

Sep 4, 2026CFO assumes accounting role
Harrow’s CFO takes over accounting role after Pollard departure, with no extra pay
Aug 10, 2026
Revenue nearly met estimates, but profitability sharply missed amid heavy investment
Aug 6, 2026
Adds TYRVAYA to its dry-eye franchise at modest upfront cost
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact